M. van der Burg

发表

Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer

T. Crook, P. Szlosarek, N. Syed, 2008, British Journal of Cancer.

Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial.

C. Coens, S. Pecorelli, B. Trimbos, 2010, Journal of the National Cancer Institute.

Molecular profiling of platinum resistant ovarian cancer

Maurice P H M Jansen, E. Berns, P. Span, 2006, International journal of cancer.

Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer

M. J. van den Bent, J. Verweij, J. Schellens, 2003, British Journal of Cancer.

Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study.

J. Vermorken, I. Teodorović, N. Colombo, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity.

M. J. van den Bent, W. van Putten, R. de Wit, 2002, European journal of cancer.

Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients.

E. Berns, M. Hooning, A. Jager, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus.

P. Siersema, R. Hoekstra, M. Polée, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer

M. J. van den Bent, J. Verweij, J. Schellens, 1997, Cancer Chemotherapy and Pharmacology.

The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot study.

J. Foekens, J. Klijn, E. Berns, 1993, European journal of cancer.

What is the role of dose-dense therapy?

J. Verweij, I. Vergote, H. V. van Doorn, 2005, International Journal of Gynecologic Cancer.

What is the role of dose-dense therapy?

J. Verweij, I. Vergote, H. V. van Doorn, 2005, International Journal of Gynecologic Cancer.

In reply to the letter by Gevaert et al.

E. Berns, M. Jansen, M. van der Burg, 2006 .

Expression of urokinase‐type plasminogen activator (uPA) and its inhibitor PAI‐1 in benign, borderline, malignant primary and metastatic ovarian tumors

J. Foekens, J. Klijn, E. Berns, 1996, International journal of cancer.

Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy.

G. Rustin, I. Vergote, G. Kristensen, 2013, Gynecologic oncology.

Receptors for hormones and growth factors and (ONCO)‐gene amplification in human ovarian cancer

J. Foekens, J. Klijn, E. Berns, 1992, International journal of cancer.

Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment

P. de Bruijn, W. Loos, T. van Gelder, 2008, Cancer Chemotherapy and Pharmacology.

High prevalence of codon 213ARG→STOP mutations of the TP53 gene in human ovarian cancer in the southwestern part of The Netherlands

J. Foekens, J. Klijn, E. Berns, 1998, International journal of cancer.

A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials).

G. Rustin, M. van der Burg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials).

G. Rustin, M. van der Burg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of intervention debulking surgery in advanced epithelial ovarian cancer: an EORTC Gynecological Cancer Cooperative Group study

M. Buyse, A. Maggioni, S. Pecorelli, 1996, International Journal of Gynecologic Cancer.

Advanced epithelial ovarian cancer: 1998 consensus statements.

J. Neijt, G. Rustin, J. Berek, 1993 .

Management of Recurrent Endometrioid Endometrial Carcinoma: An Overview

I. Vergote, H. V. van Doorn, C. Burger, 2009, International Journal of Gynecologic Cancer.

Clinical Management of Ovarian Small-Cell Carcinoma of the Hypercalcemic Type: A Proposal for Conservative Surgery in an Advanced Stage of Disease

P. Ewing-Graham, M. van der Burg, T. Helmerhorst, 2009, International Journal of Gynecologic Cancer.

Genetic alterations in ovarian borderline tumours and ovarian carcinomas.

J. Foekens, J. Klijn, M. Look, 1999, European journal of obstetrics, gynecology, and reproductive biology.

Ki‐67 staining in benign, borderline, malignant primary and metastatic ovarian tumors: Correlation with steroid receptors, epidermal‐growth‐factor receptor and cathepsin D

J. Foekens, J. Klijn, E. Berns, 1994, International journal of cancer.

Catalytic and immunologic activities of placental-like alkaline phosphatase in clinical studies. The value of PLAP in follow-up of ovarian cancer.

M. van der Burg, W. Haije, J. van Driel, 1987, Clinica chimica acta; international journal of clinical chemistry.

Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture.

E. Berns, M. Smid, M. Jansen, 2010, Gynecologic oncology.

Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865).

P. V. van Diest, E. Berns, M. Vijver, 2006, European journal of cancer.

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.

M. Piccart, M. Nooij, M. Franchi, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

G. Kenter, I. Vergote, F. Amant, 2010, The New England journal of medicine.

Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs.

E. Berns, M. Jansen, C. Burger, 2010, The international journal of biochemistry & cell biology.

BMC Cancer BioMed Central Research article Mismatch repair and treatment resistance in ovarian cancer

E. Berns, W. Dinjens, I. L. van Staveren, 2022 .

A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group.

I Vergote, P. V. van Diest, E. Berns, 1997, Journal of clinical pathology.

Preoperative Predictors for Residual Tumor after Surgery in Patients with Ovarian Carcinoma

D. de Jong, M. Eijkemans, C. Gerestein, 2008, Oncology.

The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer.

M. Buyse, N. Colombo, S. Pecorelli, 1995, The New England journal of medicine.

Phase II study of bleomycin, vindesine, mitomycin C and cisplatin (BEMP) in recurrent or disseminated squamous cell carcinoma of the uterine cervix.

M. Namer, P. Zola, C. Coens, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy

W. Hop, M. Polée, A. van der Gaast, 2003, British Journal of Cancer.

Prognostic factors in well‐differentiated early‐stage epithelial ovarian cancer

G. Fleuren, J. Trimbos, C. Cornelisse, 1993, Cancer.

Epidermal growth factor receptor in ovarian tumours: correlation of immunohistochemistry with ligand binding assay.

J. Foekens, J. Klijn, E. Berns, 1992, British Journal of Cancer.

Management of Surgical Stage III and IV Endometrioid Endometrial Carcinoma: An Overview

I. Vergote, C. Burger, M. van der Burg, 2009, International Journal of Gynecologic Cancer.

Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial.

J. Seoane, I. Vergote, R. Verheijen, 2011, European journal of cancer.

Epithelial Ovarian Cancer: Rationale for Changing the One-Fits-All Standard Treatment Regimen to Subtype-Specific Treatment

E. Berns, D. Lambrechts, F. Amant, 2014, International Journal of Gynecologic Cancer.

Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer.

J Verweij, M. J. van den Bent, J. Verweij, 2002, European Journal of Cancer.

Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer

J. Verweij, M. Polée, A. van der Gaast, 2002, British Journal of Cancer.

Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer.

M. Eijkemans, C. Gerestein, C. Burger, 2011, Anticancer research.

Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes

J. Verweij, J. Schellens, W. Loos, 1996, Cancer Chemotherapy and Pharmacology.

Recombinant interferon-gamma (immuneron): results of a phase I trial in patients with cancer.

M. van der Burg, C. Liang, M. Hirschi, 1985, Journal of biological response modifiers.

Dose-dense therapy is of benefit in primary treatment of ovarian cancer: contra.

I. Boere, M. van der Burg, P. Berns, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Serum proteomic patterns for ovarian cancer monitoring

E. Berns, T. Luider, E. Berns, 2007, International Journal of Gynecologic Cancer.

Review of dose-intense platinum and/or paclitaxel containing chemotherapy in advanced and recurrent epithelial ovarian cancer.

I. Boere, M. van der Burg, 2012, Current pharmaceutical design.

Clinical importance of molecular determinations in gynecologic patients with multiple tumors

C. Burger, H. Sleddens, M. van der Burg, 2003, Cancer.

Advanced ovarian cancer. Tumour markers.

J. Berek, G. Rustin, M. van der Burg, 1993, Annals of Oncology.

Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer.

I. Vergote, H. V. van Doorn, W. Onstenk, 2013, European journal of cancer.

The Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer.The Effect of Debulking Surgery After Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian Cancer

M. Buyse, N. Colombo, S. Pecorelli, 1996 .

Ki‐67 staining in benign, borderline, malignant primary and metastatic ovarian tumors: Correlation with steroid receptors, epidermal‐growth‐factor receptor and cathepsin D

J. Foekens, J. Klijn, E. Berns, 1994, International journal of cancer.

Prevention of cisplatin neurotoxicity with an ACTH (4–9) analogue in patients with ovarian cancer

J. C. Houwelingen, J. Heimans, R. G. van der Hoop, 1990 .

Mismatch repair and treatment resistance in ovarian cancer.

E. Berns, I. L. van Staveren, Kirsten Ritstier, 2006, BMC cancer.

Genomic aberrations relate early and advanced stage ovarian cancer

P. V. van Diest, B. Ylstra, G. Meijer, 2012, Cellular Oncology.

Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture.

E. Berns, M. Smid, M. Jansen, 2010, Gynecologic oncology.

Management of Surgical Stage III and IV Endometrioid Endometrial Carcinoma: An Overview

I. Vergote, C. Burger, M. van der Burg, 2009, International Journal of Gynecologic Cancer.

[Adjuvant chemotherapy in patients operated on for early ovarian carcinoma].

J. Trimbos, M. van der Burg, 2004, Nederlands tijdschrift voor geneeskunde.

Predictability of the survival of patients with advanced ovarian cancer.

J. Neijt, W. W. ten Bokkel Huinink, J. van Houwelingen, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.